scholarly article | Q13442814 |
P50 | author | Steven Rosenberg | Q2347448 |
P2093 | author name string | Eberlein TJ | |
Rosenstein M | |||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | immunotherapy | Q1427096 |
P304 | page(s) | 2117-2122 | |
P577 | publication date | 1984-04-01 | |
P1433 | published in | Journal of Immunology | Q3521441 |
P1476 | title | Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations | |
P478 | volume | 132 |
Q35603985 | A mouse tumor-specific transplantation antigen is a heat shock-related protein |
Q37185460 | Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells |
Q63965639 | Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2 |
Q49141356 | Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma |
Q68299436 | Concomitant treatment of MBT-2 bladder tumour by tumour necrosis factor alpha and interferon alpha in conjunction with delayed type hypersensitivity immunotherapy |
Q46658506 | Correlation of tumor specific delayed type hypersensitivity reaction and tumor protection to SV40-induced mKSA fibrosarcoma |
Q36355924 | FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens |
Q39488901 | Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy |
Q69054029 | In vivo delayed rejection of tumors and inhibition of delayed-type hypersensitivity by HT-29 human colonic adenocarcinoma cell line |
Q67532362 | Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guérin nucleic acid fraction |
Q41912662 | Mechanisms for recognition of tumor antigens and mediation of anti-tumor effect by noncytolytic Lyt-2+ T cell subset |
Q54992787 | Mediation of in vivo tumor-neutralizing activity by Lyt-2+ as well as L3T4+ T cell subsets. |
Q33848587 | Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells |
Q68907677 | The Lyt phenotype of the T cells responsible for in vivo tumor rejection in syngeneic mice |
Q44969922 | The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity |
Q39550760 | The clinical potential of interleukin-2. |
Q68915730 | The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice |
Q55283530 | The roles of CD8+ and CD4+ cells in tumor rejection. |
Q36350025 | Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells |
Q67801959 | Tumour rejection after adoptive transfer of line-10-immune spleen cells is mediated by two T cell subpopulations |
Search more.